

## 障害者政策総合研究事業（精神障害分野）中間・事後評価委員名簿

(○ : 委員長)

鹿島 晴雄	慶應義塾大学医学部 客員教授
精神医学	
	鹿島晴雄, 加藤元一郎, 本田哲三： 認知リハビリテーション。 医学書院, 東京, 1999. 10.
	Kashima H, Faloon Ian, Mizuno M, Asai M(eds.) Comprehensive Treatment of Schizophrenia. Springer, Tokyo, 2002. 1.
	鹿島晴雄, 古城慶子, 古茶大樹, 針間博彦, 前田貴記 編著： 妄想の臨床。 新興医学出版社, 東京, 2013. 6.

神尾 陽子	神尾陽子クリニック 院長/お茶の水女子大学 客員教授
<b>児童精神医学</b>	
<p><u>Kamio Y</u>, Inada N, Koyama T, Inokuchi E, Tsuchiya K, Kuroda M (2014). Effectiveness of using the Modified Checklist for Autism in Toddlers in two-stage screening of autism spectrum disorder at the 18-month health check-up in Japan. <i>J Autism Dev Disord</i>, 44(1) :194–203.</p>	
<p><u>Kamio Y</u>, Inada N, Koyama T (2013). A nationwide survey on quality of life and associated factors of adults with high-functioning autism spectrum disorders. <i>Autism</i>, 17(1) :15–26.</p>	
<p><u>Kamio Y</u>, Inada N, Moriwaki A, Kuroda M, Koyama T, Tsujii H, Kawakubo Y, Kuwabara H, Tsuchiya KJ, Uno Y, Constantino JN (2013). Quantitative autistic traits ascertained in a national survey of 22,529 Japanese schoolchildren. <i>Acta Psychiatrica Scandinavica</i>, 128(1), 45–53, DOI 10.1111/acps.12034</p>	

川上 憲人	東京大学大学院医学系研究科 特任教授／一般財団法人淳風会 代表理事理事長
<b>精神保健学</b>	
<p><u>Kawakami N</u>, Sasaki N, Asaoka H, Kuroda R, Tsuno K, Imamura K. Effects of workplace measures against COVID-19 and employees' worry about them on the onset of major depressive episodes: A 13-month prospective study of full-time employees. <i>J Affect Disord.</i> 322:187-193, 2023.</p>	
<p>Rugulies R, Aust B, Greiner BA, Arensman E, <u>Kawakami N</u>, LaMontagne AD, Madsen IEH. Work-related causes of mental health conditions and interventions for their improvement in workplaces. <i>Lancet.</i> 402(10410):1368-138, 2023.</p>	
<p>Watanabe K, Tran TTT, Sripo N, Sakuraya A, Imamura K, Boonyamalik P, Sasaki N, Tienthong T, Asaoka H, Iida M, Nguyen QT, Nguyen NT, Vu ST, Ngo TT, Luyen TT, Nguyen LD, Nguyen NTV, Nguyen BT, Matsuyama Y, Takemura Y, Nishi D, Tsutsumi A, Nguyen HT, Kaewboonchoo O, <u>Kawakami N</u>. Effectiveness of a Smartphone-Based Stress Management Program for Depression in Hospital Nurses During COVID-19 in Vietnam and Thailand: 2-Arm Parallel-Group Randomized Controlled Trial. <i>J Med Internet Res.</i> 26:e50071, 2024.</p>	

阪上 優	京都大学環境安全保健機構 教授 部門長 京都大学大学院医学研究科産業厚生医学 教授
産業精神医学、神経科学	
Jiro Takeuchi and <u>Yu Sakagami</u> . Association between autistic tendencies and mental health when studying abroad. <i>Pediatric International</i> . 2022 January ; 64 : e14724.	
Jiro Takeuchi and <u>Yu Sakagami</u> . Belief of Safety and Ethicality Associated with Agreement to Electro-Convulsive Therapy among Universities and Other Research Institution Employees. <i>Psychiatry and Clinical Neurosciences Reports</i> . 2022 ; 1 : e40.	
Miki Noda, <u>Yu Sakagami</u> , Hiroshi Tsujimoto. The psychological process of workers who access mental health services: a qualitative study focused on workers' sense of 'me as a worker'. <i>Asia Pacific Journal of Counselling and Psychotherapy</i> . 2019 ; 10(2) : 111-124.	

曾良一郎	神戸大学大学院医学研究科デジタル精神医学部門 特命教授
<b>精神医学、精神神経薬理学</b>	
Tamiya H, Ouchi A, Chen R, Miyazawa S, Akimoto Y, Kaneda Y, Sora I. Neurocognitive impairments are more severe in the binge-eating/purging anorexia nervosa subtype than in the restricting subtype. <i>Front Psychiatry.</i> Apr 16; 9: 138 (2018) doi: 10.3389/fpsyg.2018.00138	
Chiba T, Ide K, Taylor JE, Boku S, Toda H, Kanazawa T, Kato S, Horiuchi Y, Hishimoto A, Maruyama T, Yamamoto T, Shirakawa M, Sora I, Kawato M, Koizumi A. A reciprocal inhibition model of alternations between under-/overemotional modulatory states in patients with PTSD. <i>Mol Psychiatry.</i> 26(9):5023–5039 (2021).	
曾良一郎. 「物質使用症の病態」生物学的視点. 第一章 物質使用症群 Disorders due to Substance Abuse, 講座精神疾患の臨床第9巻 物質使用症又は嗜癖行動症群 性別不合 41–45 (2023)	

○	中込 和幸	国立精神・神経医療研究センター 理事長 精神神経学・臨床精神神経薬理
		Brown D, <u>Nakagome K</u> , Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenber R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. <i>Schizophr Bull</i> , 45(2) : 350–359, 2019.
		<u>Nakagome K</u> , Yokoi Y, Nakagawa A, Tani M, Nishioka G, Yoshimura N, Furukawa TA, Watanabe K, Mimura M, Iwanami A, Abe T. Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial. <i>J Affect Disord</i> . 282: 1011–1020, 2021.
		Fleischhacker WW, Podhorna J, Gröschl M, Hake S, Zhao Y, Huang S, Keefe RSE, Desch M, Brenner R, Walling DP, Mantero-Atienza E, <u>Nakagome K</u> , Pollentier S. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. <i>Lancet Psychiatry</i> . 8(3) : 191–201, 2021.